ABSTRACT
The term CKD includes the development and evolution of chronic renal failure of many different origins (1). Trials investigating the effect of different therapies on the evolution of renal function have usually included patients with early or established primary renal diseases and/or diabetic nephropathy. Most patients presented at entry with macroalbuminuria to ensure that a short duration of follow-up (2 years in most cases) enabled the differentiation of the therapies tested with placebo or between themselves for the protection of renal function. In the case of microalbuminuria the primary aim has been the change in this parameter without considering the evolution of renal function through changes in serum creatinine or estimated GFR.
